Monday, March 17, 2008

Glenmark to add 11 drugs to US portfolio

Glenmark Pharmaceuticals, the US subsidiary of Glenmark Pharmaceuticals, is planning to introduce 11 dermatological products in the next one year.

The company has acquired the US marketing rights for a range of clobetasol propionate products, which is used to treat ailments like eczema and psoriasis. It is also dispensed to counter auto-immune presentations such as Alopecia areata (hair loss due to auto-immune diseases) and Lichen planus (auto immune skin nodules).

No comments:

Post a Comment